Cargando…

A pipeline for copy number profiling of single circulating tumour cells to assess intrapatient tumour heterogeneity

Intrapatient tumour heterogeneity is likely a major determinant of clinical outcome in cancer patients. To assess heterogeneity in a minimally invasive manner, methods to perform single circulating tumour cell (CTC) genomics at high resolution are necessary. However, due to the rarity of CTCs, devel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deger, Teoman, Mendelaar, Pauline A. J., Kraan, Jaco, Prager‐van der Smissen, Wendy J. C., van der Vlugt‐Daane, Michelle, Bindels, Eric M. J., Sieuwerts, Anieta M., Sleijfer, Stefan, Wilting, Saskia M., Hollestelle, Antoinette, Martens, John W. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394233/ https://www.ncbi.nlm.nih.gov/pubmed/34964258 http://dx.doi.org/10.1002/1878-0261.13174

Ejemplares similares

The 29.5 kb APOBEC3B Deletion Polymorphism Is Not Associated with Clinical Outcome of Breast Cancer
por: Liu, Jingjing, et al.
Publicado: (2016)

Circulating tumour cells are associated with histopathological growth patterns of colorectal cancer liver metastases
por: Meyer, Y. M., et al.
Publicado: (2022)

ESR1 Methylation Measured in Cell-Free DNA to Evaluate Endocrine Resistance in Metastatic Breast Cancer Patients
por: Bos, Manouk K., et al.
Publicado: (2022)

Anti-Epithelial Cell Adhesion Molecule Antibodies and the Detection of Circulating Normal-Like Breast Tumor Cells
por: Sieuwerts, Anieta M., et al.
Publicado: (2009)

Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel
por: de Kruijff, Ingeborg E., et al.
Publicado: (2019)

Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients
por: Beije, Nick, et al.
Publicado: (2017)

A Systematic Review of the Use of Circulating Cell-Free DNA Dynamics to Monitor Response to Treatment in Metastatic Breast Cancer Patients
por: Jongbloed, Elisabeth M., et al.
Publicado: (2021)

Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications
por: Krebs, M.G., et al.
Publicado: (2021)

Prospective Evaluation of a Circulating Tumor Cell Sensitivity Profile to Predict Response to Cisplatin Chemotherapy in Metastatic Breast Cancer Patients
por: de Kruijff, I. E., et al.
Publicado: (2021)

Defining the dimensions of circulating tumor cells in a large series of breast, prostate, colon, and bladder cancer patients
por: Mendelaar, Pauline A. J., et al.
Publicado: (2020)

Detection of tumor-derived extracellular vesicles in plasma from patients with solid cancer
por: Vitale, Silvia R., et al.
Publicado: (2021)

Response to comment on “Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications”
por: Krebs, M.G., et al.
Publicado: (2021)

Confirmation of a metastasis-specific microRNA signature in primary colon cancer
por: Coebergh van den Braak, Robert R. J, et al.
Publicado: (2018)

Gene length corrected trimmed mean of M-values (GeTMM) processing of RNA-seq data performs similarly in intersample analyses while improving intrasample comparisons
por: Smid, Marcel, et al.
Publicado: (2018)

Letter re: ‘Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications’
por: Sullivan, W.G., et al.
Publicado: (2021)

Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor()
por: Beije, Nick, et al.
Publicado: (2016)

High‐throughput isolation of circulating tumor DNA: a comparison of automated platforms
por: van Dessel, Lisanne F., et al.
Publicado: (2018)

Genome‐wide aneuploidy detected by mFast‐SeqS in circulating cell‐free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancer
por: Mendelaar, Pauline A. J., et al.
Publicado: (2022)

Mitochondrial DNA content in breast cancer: Impact on in vitro and in vivo phenotype and patient prognosis
por: Weerts, Marjolein J.A., et al.
Publicado: (2016)

Adaptive intrapatient dose escalation of cisplatin in combination with low-dose vp16 in patients with nonsmall cell lung cancer
por: Schellens, J H M, et al.
Publicado: (2003)

Treponema pallidum Subspecies Pallidum Intrapatient Homogeneity at Various Body Locations in Men with Infectious Syphilis
por: Zondag, H. C. A., et al.
Publicado: (2022)

Self-Seeding Microwells to Isolate and Assess the Viability of Single Circulating Tumor Cells
por: Andree, Kiki C., et al.
Publicado: (2019)

Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers
por: Kriege, Mieke, et al.
Publicado: (2015)

Measuring antigen expression of cancer cell lines and circulating tumour cells
por: Mentink, Anouk, et al.
Publicado: (2023)

Circulating Tumour DNA as Biomarker for Colorectal Liver Metastases: A Systematic Review and Meta-Analysis
por: Wullaert, Lissa, et al.
Publicado: (2023)

Circulating tumour cells to drive the use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer
por: Beije, N., et al.
Publicado: (2022)

AR splice variants in circulating tumor cells of patients with castration‐resistant prostate cancer: relation with outcome to cabazitaxel
por: Sieuwerts, Anieta M., et al.
Publicado: (2019)

Tumor-agnostic ctDNA levels by mFAST-SeqS in first-line HR-positive, HER2 negative metastatic breast cancer patients as a biomarker for survival
por: Verschoor, Noortje, et al.
Publicado: (2023)

Recurrent HOXB13 mutations in the Dutch population do not associate with increased breast cancer risk
por: Liu, Jingjing, et al.
Publicado: (2016)

mFast‐SeqS‐based aneuploidy score in circulating cell‐free DNA is a prognostic biomarker in prostate cancer
por: Isebia, Khrystany T., et al.
Publicado: (2023)

High-throughput and affordable genome-wide methylation profiling of circulating cell-free DNA by methylated DNA sequencing (MeD-seq) of LpnPI digested fragments
por: Deger, Teoman, et al.
Publicado: (2021)

miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs
por: Riaz, Muhammad, et al.
Publicado: (2013)

Endothelial CD276 (B7-H3) expression is increased in human malignancies and distinguishes between normal and tumour-derived circulating endothelial cells
por: Kraan, J, et al.
Publicado: (2014)

Molecular characteristics of circulating tumor cells resemble the liver metastasis more closely than the primary tumor in metastatic colorectal cancer
por: Onstenk, Wendy, et al.
Publicado: (2016)

Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer
por: Godinho, M F E, et al.
Publicado: (2010)

Prognostic value of circulating tumour cells for early recurrence after resection of colorectal liver metastases
por: Lalmahomed, Z S, et al.
Publicado: (2015)

Circulating tumour DNA as biomarker for rectal cancer: A systematic review and meta-analyses
por: van Rees, Jan M., et al.
Publicado: (2023)

Influence of secondary inoculum of tumour cells on growth of primary tumour.
por: van der Gaag, R., et al.
Publicado: (1978)

Intrapatient variability in plasma rifampicin & isoniazid in tuberculosis patients
por: Kumar, A. K. Hemanth, et al.
Publicado: (2018)

Impact of panel design and cut-off on tumour mutational burden assessment in metastatic solid tumour samples
por: Mankor, Joanne M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lu1o0173ghr0112fveuuhej6vj